U.S. markets closed

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real Time Price. Currency in DKK
Add to watchlist
26.38-0.38 (-1.42%)
At close: 4:59PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.76
Bid26.08 x 0
Ask26.40 x 0
Day's Range25.74 - 26.90
52 Week Range22.02 - 109.10
Avg. Volume209,829
Market Cap922.039M
Beta (5Y Monthly)0.70
PE Ratio (TTM)N/A
EPS (TTM)-25.55
Earnings DateAug 31, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est155.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ORPHA.CO

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      50 Biggest Movers From Yesterday

      Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target. Waitr Holdings Inc (NASDAQ: WTRH) gained 58.5% to close at $1.27 after Morgan Stanley reported a 10.3% passive stake in the company. Sono-Tek Corporation (NASDAQ: SOTK) jumped 44.2% to close at $6.49. Sono-Tek reported second-quarter FY22 net sales growth of 17% year-on-year to $4.07 million. Sono

    • GlobeNewswire

      Modified long-term share-based incentive program for 2021

      Orphazyme A/SCompany announcement No. 23/2021Company Registration No. 32266355 Copenhagen, Denmark, October 7, 2021 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 (the “LTIP”) with the view to retaining members of the Executive Management and other employees of the Group, while also creating an incentive for a positive share price development and corporate performance for the benefit of the

    • Benzinga

      The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

      Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (NASDAQ: AVDL) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Cytokinetics, Incorporated (NASDAQ: CYTK) Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) Legend Biotech Corporation (NASDAQ: LEGN) Merck & Co, Inc. (NYSE: MRK) Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) Legend Biot